The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / What Rheumatologists Need to Know about Diagnosing and Managing Interstitial Lung Disease (ILD)

What Rheumatologists Need to Know about Diagnosing and Managing Interstitial Lung Disease (ILD)

December 1, 2012 • By Aryeh Fischer, MD, and Jeff Swigris, DO, MS

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Interstitial lung disease (ILD) refers to a large group of diffuse parenchymal lung disorders characterized histologically by inflammation, fibrosis, or a combination of the two (see Table 1). Common causes of ILD include exposure to environmental antigens (e.g., avian proteins) or occupational dusts (e.g., silica or asbestos), and ILD is a common lung manifestation of connective tissue disease (CTD). Although ILD may result from any of the classifiable CTDs, patients with systemic sclerosis (SSc), poly-/dermatomyositis (PM/DM), or rheumatoid arthritis (RA) appear to carry the greatest risk for developing CTD-associated ILD (CTD-ILD). There is growing appreciation that ILD may be the first manifestation of a CTD; in fact, some experts believe that ILD may be the only manifestation of a CTD.1 In this report, we aim to discuss the epidemiology, classification, and clinical features of CTD-ILD and to highlight some areas of uncertainty and gaps in our understanding of this condition.

You Might Also Like
  • MUC5B Promoter Variant Associated with RA with Interstitial Lung Disease
  • When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients
  • CCL2 Cytokine Serves as Biomarker in Interstitial Lung Disease
Explore This Issue
December 2012

Prevalence of CTD-ILD

The true incidence and prevalence of ILD occurring in association with CTD are unknown. Published estimates vary because of differences in study design, in particular how cohorts are identified and the methods used to define the presence of ILD. For example, investigators who use autopsy data to confirm the presence of ILD undoubtedly overestimate the prevalence of clinically significant ILD. Prevalence estimates for CTD-ILD range from 25–90% for SSc, from 5–70% for PM/DM, from 2–63% for RA, from 8–38% for Sjögren’s disease, and from 3–38% for systemic lupus erythematosus.2 We believe that clinically significant CTD-ILD probably occurs more commonly than many rheumatologists appreciate, yet less often than pulmonologists believe. Clearly, more research is needed to better understand the epidemiology of CTD-ILD.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

click for large version
Table 1: Classification of ILDs

Classification of CTD-ILD Based on Histopathology

To characterize the histologic patterns in surgical lung biopsy (SLBx) specimens from patients with ILD, including those with CTD-ILD, pathologists use the classification scheme developed for the idiopathic interstitial pneumonias (IIPs).3 The IIPs are a group of seven ILDs of unknown cause, with potentially overlapping clinical and radiological features but different prognoses (see Table 1). Over the years, a challenging nomenclature and ever-changing classification scheme has created confusion around the IIPs. Also clouding understanding is the fact that, although the seven histologic patterns decisively distinguish one IIP from another, the patterns are not specific to “idiopathic” disease and may occur in ILD of any cause. For example, the fibrotic pattern of usual interstitial pneumonia (UIP pattern) has a number of potential causes, including chemotherapy-induced ILD, hypersensitivity pneumonitis, sarcoidosis, or any of the CTDs. The UIP pattern is the most common histological pattern in patients with IIP. However, among patients with CTD-ILD who undergo SLBx, the pattern of nonspecific interstitial pneumonia (NSIP pattern) is most frequently identified. It is unclear whether the NSIP pattern appears to predominate because of significant selection bias: relatively few patients with CTD-ILD undergo SLBx.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 7 | Single Page

Filed Under: Conditions, Guidelines, Research Reviews, Rheumatoid Arthritis Tagged With: Diagnosis, ILD, imaging, Interstitial Lung Disease, patient care, Research, Rheumatoid arthritis, rheumatologist, Sjögren's syndrome, TreatmentIssue: December 2012

You Might Also Like:
  • MUC5B Promoter Variant Associated with RA with Interstitial Lung Disease
  • When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients
  • CCL2 Cytokine Serves as Biomarker in Interstitial Lung Disease
  • Cyclophosphamide for Connective Tissue Disease-Associated Interstitial Lung Disease

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)